COL6A3 and breast carcinoma: To our knowledge, there are no reports validating the response to any of these drug classes in preclinical models perturbing COL6A3. Nevertheless, these drug classes represent potentially exciting, targeted therapies or combination therapies to combat tumors that express high levels of COL6A3 like breast cancer, UPS, and pleomorphic dermal sarcoma (PDS).